Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12707168 | 0.89 | TDP1 (0.45) | TDP1ALDH1A1FFAR3MGAMGAA | |
| SCHEMBL14536188 | 0.89 | TDP1 (0.45) | TDP1ALDH1A1FFAR3MEN1KMT2A | |
| SCHEMBL12035873 | 0.88 | — | — | |
| SCHEMBL20438307 | 0.84 | TDP1 (0.41) | TDP1 | |
| SCHEMBL17875398 | 0.83 | — | — | |
| SCHEMBL22872255 | 0.83 | TDP1 (0.39) | TDP1ALDH1A1GAA | |
| SCHEMBL18929522 | 0.81 | — | — | |
| SCHEMBL22415486 | 0.79 | TDP1 (0.36) | TDP1 | |
| SCHEMBL22336404 | 0.79 | GAA (0.50) | TDP1ALDH1A1GAATSHR | |
| SCHEMBL14577056 | 0.79 | TDP1 (0.41) | TDP1ALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470964-B2 | Peptides derived from NCAM (FGLs) | ENKAM PHARMACEUTICALS A/S (DK) | 2013-06-25 | — | — | US | disclosed |
| US-20120115796-A1 | Novel Spacer Moiety for Poly(ehtylene Glycol) Modified Peptide Based Compounds | AFFYMAX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115796-A1 | Novel Spacer Moiety for Poly(ehtylene Glycol) Modified Peptide Based Compounds | AFFYMAX, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8088884-B2 | Multi-armed forms of activated polyoxazoline and methods of synthesis thereof | SERINA THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100249368-A1 | Multi-Armed Forms of Activated Polyoxazoline and Methods of Synthesis Thereof | SERINA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | TDP1 316/4885ALDH1A1 2071/4885FFAR3 2985/4885 |
| US-20120115796-A1 | Novel Spacer Moiety for Poly(ehtylene Glycol) Modified Peptide Based Compounds | NGLY1, HM13, YWHAZ | TDP1 4525/4885ALDH1A1 4441/4885FFAR3 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.